Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Ali Aminian
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07027969CT.gov Metabolic Surgery for Atrial Fibrillation Elimination | — | Not Yet Recruiting | — | — | — |
NCT07275697CT.gov Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study | — | Not Yet Recruiting | — | — | — |
NCT06184633CT.gov DUTCH Weight Control in Atrial Fibrillation Study | — | Recruiting | — | — | — |
NCT04885634CT.gov Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients | — | Withdrawn | — | — | — |
NCT06660134CT.gov Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Atrial Fibrillation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Semaglutide (this asset) | Ali Aminian | Approved | BB · 67 |
| Edoxaban | National Taiwan University Hospital | P4 | A |
| Dabigatran | Pfizer | P4 | BBB |
| Rivaroxaban | VA Office of Research and Development | P4 | BBB |
| Apixaban | Regeneron Pharmaceuticals | P4 | BBB |
| Warfarin | Pfizer | P4 | BBB |
| Aspirin | Yonsei University | P4 | BBB |
| 3-(.ALPHA.-ACETONYL-P-NITROBENZYL)-4-HYDROXYCOUMARIN | University of Edinburgh | P4 | BB |
| Atecegatran Fexenetil | AstraZeneca | P2 | BB |
+32 more in the Atrial Fibrillation cohort
Other indications for Semaglutide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Disease | — | P4 | A · 81 |
| Polycystic Ovary Syndrome | — | P4 | BBB · 79 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Semaglutide in Atrial Fibrillation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/semaglutide-atrial-fibrillation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →